摘要
Abstract
Objective To observe the effect of atorvastatin on vascular function ,blood glucose and lipid metabolism state in patients with type 2 diabetic nephropathy. Methods One hundred and eighty cases of diabetic nephropathy were ran-domly divided into 2 groups, the control group and the observation group with 90 cases in each group, the control group uses the routine treatment, and the observation group was treated with routine therapy and atorvastatin. Before and after treatment, related indices of vascular function in reactive hyperemia increased percentage ( FMD) and serum nitric oxide ( NO) , 3-nitro tyrosine (3-NT), von Willebrand factor (vWF), plasminogen activator inhibitor type 1 (PAI-1) level and lipid metabolism of total cholesterol ( TC) , triglyceride ( TG) , low density lipoprotein cholesterol ( LDL-C) , high density lipoprotein cholesterol ( HDL-C) , the related indicators and sugar metabolism, glycosylated hemoglobin ( HbA1c ) , fasting plasma glucose ( FPG) , 2 hour postprandial blood glucose (2 hPG) and pancreaticβcell secretion index (HOMA-β) and insulin resistance index (HO-MA-IR) were compared between the 2 groups. Results After 6 and 12 weeks treatment, HbA1c , FPG, 2 hPG level and HO-MA-IR values in observation group were significantly lower than those of control group( P <0. 05),and HOMA-βwas signifi-cantly higher than that of control group ( P <0. 05). TC, TG, LDL-C levels in the observation group were significantly lower than that of control group ( P <0. 05), and HDL-C level was significantly higher than that of control group ( P <0. 05). FMD and the serum level of NO in the observation group was significantly higher than that of control group ( P <0. 05), and the 3-NT, vWF and PAI-1 levels were significantly lower than that of control group ( P <0. 05). Conclusion Atorvastatin can effectively regulate the metabolism of blood lipid in patients with type 2 diabetic nephropathy, and can improve the glucose metabolism, protecting vascular function.关键词
糖尿病肾病/血管功能/代谢/阿托伐他汀Key words
Diabetic nephropathy/Vascular function/Metabolism/Atorvastatin
